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Abstract
Background Many decisions can be understood in terms of actors
valuations of beneﬁts and costs. The article investigates whether this
is also true of patient medical decision making. It aims to investigate
(i) the importance patients attach to various reasons for and against
nine medical decisions; (ii) how well the importance attached to
beneﬁts and costs predicts action or inaction; and (iii) how such
valuations are related to decision conﬁdence.
Methods In a national random digit dial telephone survey of U.S.
adults, patients rated the importance of various reasons for and
against medical decisions they had made or talked to a health-care
provider about during the past 2 years. Participants were 2575
English-speaking adults age 40 and older. Data were analysed by
means of logistic regressions predicting action ⁄ inaction and linear
regressions predicting conﬁdence.
Results Aggregating individual reasons into those that may be
regarded as beneﬁts and those that may be regarded as costs, and
weighting them by their importance to the patient, shows the
expected relationship to action. Perceived beneﬁts and costs are also
signiﬁcantly related to the conﬁdence patients report about their
decision.
Conclusion The factors patients say are important in their medical
decisions reﬂect a subjective weighing of beneﬁts and costs and
predict action ⁄ inaction although they do not necessarily indicate
that patients are well informed. The greater the diﬀerence between
the importance attached to beneﬁts and costs, the greater patients
conﬁdence in their decision.
doi: 10.1111/j.1369-7625.2011.00739.x
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Introduction
The assumption underlying many theories of
action, for example, the theory of reasoned
action and its oﬀshoots in psychology (1,2),
leverage-salience theory in survey methodology
(3) and various cost-beneﬁt perspectives in eco-
nomics (cf. 4), is that actors will behave in
accordance with the importance of the perceived
costs and beneﬁts of a decision to them. Cost-
beneﬁt considerations have been shown to
inﬂuence decisions to participate in biomedical
research (4), in clinical trials (5,6) and in social
research (7–11). The speciﬁc factors for or
against a decision (i.e. its perceived beneﬁts and
drawbacks, or costs1) will, of course, vary
between decision contexts.
The question we examine in the present article
is a speciﬁc instance of this more general theory
– namely, whether patients who made a variety
of medical decisions behaved in accordance with
the perceived importance of the beneﬁts and
costs of the decision to them. We also examine
whether patients perceptions of costs and ben-
eﬁts are related to the conﬁdence they have that
their ﬁnal decision was the right one for them.
It is almost axiomatic that integrating
patients own goals and concerns into medical
decisions is essential to patient-centred care and
good decisions (12,13). Sepucha et al. (14),
reviewing the literature on measuring the quality
of a medical decision, argue that measuring what
matters to patients is essential to measuring how
well decisions, on average, are likely to reﬂect
their goals and concerns. Thus, measuring what
was important to patients faced with common
medical decisions was an essential step in this
project, which was designed to describe how
such decisions were being made.
The article examines nine speciﬁc medical
decisions (initiating cholesterol, blood pressure
or anti-depressant medication; electing hip ⁄
knee, cataract or lower-back surgery; or under-
going screening for colon, breast or prostate
cancer) falling into three broad categories:
medication initiation, elective surgery and can-
cer screening. Our hypothesis is that patients
decide to act with respect to each of these types
of decisions if, on balance, the importance of
factors regarded as beneﬁts of a particular
intervention outweighs the importance of factors
regarded as costs.
Methods
The decisions survey
In a list-assisted national telephone survey car-
ried out in 2006–2007, we investigated how a
probability sample of 3010 English-speaking
adults 40 years and older reported making nine
frequent medical decisions. Full details of the
sampling frame, instrument development, data
collection methodology, response rates and
analysis weights can be found in the Summary of
Methods (15). Further information can also be
found in Zikmund-Fisher et al. (16). All proce-
dures and instruments were approved by insti-
tutional review boards at the University of
Michigan and Ann Arbor Veterans Aﬀairs
Medical Center.
The National Survey of Medical Decisions
deﬁned a medical decision as having taken place
if a patient had either taken a medical action or
discussed taking that action with a health-care
provider (HCP). To minimize recall bias while
maximizing available information, only decisions
that occurred within 2 years of the interview date
were assessed. To be eligible for the survey,
sample members had to have made at least one
medical decision within that period of time.
Of the 3010 persons interviewed, 2575
reported having discussed or acted on at least
one medical decision and constitute the sample
for the present analysis. The weighted response
rate to the survey (American Association for
Public Opinion Research RR4) was 51.6%. Of
those eligible to participate, 86.5% co-operated.
The average interview length was 27.7 min.
Participants were selected for detailed follow-
up questions for up to two decisions, with selec-
tion probabilities designed to oversample rarer
1In this article, costs is used in the general sense of draw-
backs. When monetary costs are intended, that term is used,
instead.
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decisions. Some 82.2% of those interviewed had
made at least one decision in the preceding
2 years, and 56.0% had made two or more. Some
91% of the sample reported that they had health
insurance, a ﬁgure comparable to that of the
general population over 40 (17), and of these,
91% reported that their plan covered prescrip-
tion medications. Almost 90% of the sample
reported having a primary HCP. More than half
(56.7%) of the sample was female; 26.5% were in
their 40s, 29.5% in their 50s, 21.3% in their 60s
and 22.8% in their 70s or above. Only 43.9% had
a high school education or less, and 86.7% of the
sample was Caucasian non-Hispanic.
Independent variables: reasons for patients
decisions
The survey had several aims. Chief among these
was exploring the process of medical decision
making, including how well informed patients
were about the decision (18). Still another focus
of the study was patients ratings of the impor-
tance of a number of factors with respect to the
three types of medical decisions described ear-
lier, and the role these played in their decision.
For each of the nine speciﬁc conditions falling
into these three categories, a number of state-
ments were developed, half of which were
intended to describe beneﬁts of the speciﬁc
action, and half to describe its costs or draw-
backs. These reasons were developed after
extensive discussions among the research team
following focus groups previously conducted by
the Foundation for Informed Medical Decision
Making with patients facing decisions about
back, knee, and hip surgery and screening for
colon and prostate cancer. Respondents were
asked to rate how important each reason had
been to them in making a particular decision.
The exact question read as follows:
When [thinking ⁄ deciding] about whether or not to
[medical decision], some issues may be very
important to you, while others may be less
important. On a scale from 0 to 10, where 0 means
not at all important to you and 10 means extremely
Table 1 List of possible reasons for decisions, by type of decision, variable name and cost-beneﬁt coding
Decision Reason Variable name
Beneﬁt (+) ⁄
Cost ())
All decisions Following your HCPs advice Follow HCP advice + ⁄)
The amount of money you would have to pay Monetary cost )
Screening Fear of getting cancer Fear +
Finding the cancer early Find early +
The chance that the test might miss a cancer thats really there False neg )
The chance that the test might give a false alarm when you do
not in fact have cancer
False pos )
The discomfort of the test Discomfort )
The risks and possible complications of the test Complications )
Surgery Feeling ⁄ seeing better Feel ⁄ see better +
Being able to do things you could not otherwise do Do more +
How long it would take you to recover Recovery Time )
The chance that the procedure would not help No improvement )
The risks and possible complications of surgery Complications )
Medications Feeling better Feel better +
Being able to function better Function better +
Getting your cholesterol ⁄ blood pressure to a desirable level Good level +
Lowering your risk of a heart attack or stroke Lower risk +
How long you would have to take the medication How long meds )
Avoiding medication Avoid meds )
The chance that the medication would not help you No improvement )
The risks and complications of the medication Complications )
HCP, health-care provider.
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Table 2 (a) Medication initiation, (b) cancer screening, and (c) surgery: means and standard deviations of importance ratings
(0–10)
(a)
Importance variable*
Cholesterol-lowering
medication
Blood pressure
medication Anti-depressants
N Mean (SD) N Mean (SD) N Mean (SD)
Follow HCP advice (+ ⁄)) 772 8.53 (2.30) 771 9.09 (1.83) 396 8.10 (3.15)
Lower risk (+ ⁄)) 768 9.37 (1.74) 776 9.55 (1.61) – –
Good level (+) 765 9.05 (2.12) 767 9.55 (1.39) – –
Complications ()) 759 7.67 (3.45) 766 7.10 (3.89) 395 7.82 (3.51)
Monetary cost ()) 762 5.89 (4.46) 765 5.87 (4.59) 393 5.68 (4.84)
No improvement ()) 725 6.26 (3.94) 732 6.17 (4.28) 377 6.55 (4.32)
How long meds ()) 749 7.07 (3.93) 759 6.72 (4.48) 386 7.10 (4.33)
Avoid meds ()) 747 6.39 (4.27) 748 6.02 (4.65) 390 5.90 (4.59)
Feel better (+) – – – – 395 9.26 (2.28)
Function better (+) – – – – 394 9.20 (2.50)
Mean beneﬁts (mean pros) (+) 772 9.05 (1.72) 778 9.43 (1.31) 396 9.01 (2.13)
Mean costs (mean cons) ()) 774 6.69 (2.90) 778 6.44 (3.00) 399 6.67 (2.93)
Difference between mean beneﬁts
and costs (mean_diff) (+)
771 2.38 (3.17) 777 2.99 (3.03) 396 2.39 (3.28)
(b)
Importance variable*
Colon cancer screening
Breast cancer
screening
Prostate cancer
screening
N Mean (SD) N Mean (SD) N Mean (SD)
Follow HCP advice (+ ⁄)) 840 8.42 (2.43) 862 8.69 (2.30) 369 8.55 (2.42)
Fear (+) 835 6.12 (3.88) 862 6.97 (3.53) 372 6.93 (3.71)
Find early (+) 835 9.21 (2.06) 863 9.41 (1.80) 369 9.12 (2.34)
False neg ()) 800 5.75 (4.05) 842 6.93 (3.41) 362 5.92 (3.85)
False pos ()) 804 4.47 (3.90) 840 5.72 (3.53) 365 5.00 (3.81)
Complications ()) 828 4.86 (3.94) – – – –
Discomfort ()) 826 4.85 (4.00) 860 5.06 (3.76) 365 2.94 (3.65)
Monetary cost ()) 829 4.06 (4.39) 851 3.99 (4.12) 364 3.46 (4.17)
Mean beneﬁts (mean pros) (+) 841 7.86 (2.29) 871 8.31 (2.05) 373 8.16 (2.31)
Mean Costs (mean cons) ()) 843 4.85 (2.88) 869 5.44 (2.62) 372 4.35 (2.86)
Difference between mean beneﬁts
and costs (mean_diff) (+)
840 3.03 (3.08) 869 2.87 (2.87) 372 3.80 (3.23)
(c)
Importance variable*
Knee–Hip surgery Cataract surgery Lower-back surgery
N Mean (SD) N Mean (SD) N Mean (SD)
Follow HCP advice (+ ⁄)) 138 8.70 (2.89) 198 9.29 (1.92) 115 8.10 (3.32)
Do more (+) 138 9.22 (2.34) 189 8.12 (4.18) 114 9.15 (3.02)
Complications ()) 136 7.62 (4.22) 189 6.44 (4.74) 113 7.93 (4.61)
Monetary cost ()) 136 5.36 (5.90) 193 5.58 (5.32) 115 5.66 (6.49)
No improvement ()) 130 6.73 (5.37) 185 6.27 (5.04) 111 8.19 (4.03)
Recovery time (+) 137 7.86 (4.01) 190 6.54 (4.68) 114 8.08 (4.54)
Feel ⁄ see better (+) – – 197 9.31 (2.54) 115 9.35 (2.09)
Mean beneﬁts (mean pros) (+) 138 9.00 (2.38) 198 8.72 (2.86) 115 8.89 (2.37)
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important, how important was each of the fol-
lowing in your [thinking ⁄decision] about whether
or not to [medical decision]?
The interviewer repeated the scale as neces-
sary for each of the reasons.
The complete list of reasons is shown in
Table 1, separately for each type of decision.
Table 1 also shows the variable name associated
with each reason as well as whether the reason
was coded as a beneﬁt or a cost. Note that
following the HCPs advice could be coded as
either a beneﬁt or a cost: if the doctor recom-
mended against an action, it was coded as a
cost so far as taking action is concerned; if the
doctor recommended an action, it was coded as
a beneﬁt. Those few respondents who reported
receiving conﬂicting advice with respect to a
particular decision, perhaps because they had
consulted more than one HCP, were not scored
on that decision. A maximum of ten reasons was
applicable to a given decision, but for some
decisions, as few as seven were asked about.
Although the list is virtually identical for the
three speciﬁc conditions under each decision
type, they vary from one type to another,
because these have diﬀerent speciﬁc beneﬁts and
costs. Descriptive statistics for each variable for
each condition are shown in Table 2a–c.
Analysis
To test the hypothesis that the preponderance of
beneﬁts over costs predicts action, we created a
Mean Diﬀerence score, described below, and
analysed its predictive value by means of logistic
regressions that also control for respondents
demographic characteristics. In addition, we
examined the usefulness of two other predictors
of action: separate indexes of beneﬁts (Mean
Pros) and costs (Mean Cons), and the impor-
tance of following the HCPs advice. Descriptive
statistics for these variables are also shown in
Table 2a–c. The hypothesis that conﬁdence in
the decision was related to the preponderance of
beneﬁts over costs was tested by means of linear
regressions.
The analyses used the SURVEYLOGISTIC
procedure in SAS 9.2, which adjusts the stan-
dard errors of the estimates to reﬂect the
complex nature of the sample design. The
analysis also accounts for the fact that some
participants are represented twice in the data
set, by adjusting for the non-independence of
some observations.
Results
It is reasonable to assume that human action, in
general, is governed by cost-beneﬁt calculations,
although these may not be well informed or
weighted in a way doctors would consider
rational (19–21). Speciﬁcally, we formulated the
following hypotheses about medical decisions:
(i) The more the perceived beneﬁts of a decision
outweigh the perceived costs, the more likely the
respondent will be to take action; (ii) the more
the perceived beneﬁts of a decision outweigh the
perceived costs, the greater the respondents
conﬁdence in the decision will be.
As described in the preceding section, per-
ceived costs and beneﬁts were assessed by means
of questions about how important a series of
Table 2 Continued
(c)
Importance variable*
Knee–Hip surgery Cataract surgery Lower-back surgery
N Mean (SD) N Mean (SD) N Mean (SD)
Mean costs (mean cons) ()) 139 6.98 (3.41) 198 6.51 (3.67) 115 7.55 (3.10)
Difference between mean beneﬁts
and costs (mean_diff) (+)
138 2.03 (3.85) 196 2.22 (3.74) 115 1.34 (3.66)
HCP, health-care provider.
*For a deﬁnition of variables, see Table 1. Beneﬁts = (+), cost = ()). The range of responses for each variable is 0–10 except for the difference
between mean beneﬁts and costs, where minima range from )10 to +10.
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reasons had been to the respondent in reaching a
particular decision. We then averaged the posi-
tive (beneﬁt) and negative (cost) ratings (on the
0–10 scale) separately for each respondent asked
about a speciﬁc decision and computed the dif-
ference between the two. For example, if a
respondent rated the importance of three costs
as 5, 7 and 10, respectively, the average cost
rating for that module would be 7.33. If the
same respondent rated the importance of four
beneﬁts as 8, 8, 10 and 10, respectively, the
average beneﬁt rating for that module would be
9.0. The diﬀerence (beneﬁts-costs) would be
+1.7, indicating a balance in favour of per-
ceived beneﬁts. Positive values on the mean
diﬀerence score indicate that beneﬁts are rated
as more important than costs, while negative
values indicate that costs are weighed as more
important than beneﬁts, on average; a score of
zero means beneﬁts and costs are rated equally
important, on average.
Results of the analyses testing Hypothesis 1
are shown in Table 3a–c, separately for the
three types of decisions. The dependent vari-
able for each analysis is a binary variable,
whether or not in the past 2 years the
respondent began taking medication, had
elective surgery or had a screening test. The
predictors are the individual medications,
screening tests or surgeries within each type of
condition; the diﬀerence between the average
positive and negative importance scores; the
interaction terms between the individual con-
ditions and the mean diﬀerence scores (to
account for diﬀerences between individual
medications, screening tests and surgeries); and
gender, age, race, Hispanic origin and educa-
tion, to control for diﬀerences in exposure to
the diﬀerent medical conditions.
As predicted, the diﬀerence between the
importance of the average beneﬁts and the
average costs is signiﬁcant and positive in all
three models. However, in the medications
model (Table 3a), the two interaction terms are
signiﬁcant and negative, cancelling out the
estimated overall eﬀect of the beneﬁt-cost dif-
ference on the likelihood of taking action. A
one-point change in the diﬀerence between the
mean beneﬁts and mean costs (i.e. a 1-unit
change) is associated with an odds ratio of
medication initiation of 1.17 for depression,
while the odds ratios are not signiﬁcantly dif-
ferent from 1 for the other two medication
types. Thus, the signiﬁcance of the overall eﬀect
for medications is due largely to medications
for depression. It is possible that in the case of
blood pressure and cholesterol medications,
patients are merely following the HCPs advice,
which serves as a heuristic for a net beneﬁt-cost
calculation.
None of the interaction eﬀects in the other
two models is statistically signiﬁcant. In the
case of screening (Table 3b), a 1-unit increase
in the diﬀerence score is associated with an
increase in the odds of undergoing screening of
1.33 for breast cancer, 1.27 for prostate cancer
and 1.08 for colon cancer. In the case of sur-
gery (Table 3c), a 1-unit increase in the diﬀer-
ence score is associated with an increase in the
odds of surgery of 1.49 for lower-back pain,
1.18 for knee ⁄hip replacement and 1.16 for
cataracts.
We also examined two alternative models
evaluating the eﬀects of beneﬁts and costs on
medical decision making. The ﬁrst of these
assesses the independent eﬀects of beneﬁts and
costs on action with respect to medications,
surgery and screening. The results largely par-
allel those reported in Table 3a–c but provide
more speciﬁc information about whether it is the
importance attached to beneﬁts or that attached
to costs which appears to be driving the decision
(data not shown). For medications, the impor-
tance of perceived beneﬁts is signiﬁcantly related
to taking action, but the importance of perceived
costs, though negative, is not; the interaction
between high blood pressure and the importance
of perceived beneﬁts is signiﬁcant and negative,
while that between cholesterol and perceived
beneﬁts is also negative though not signiﬁcant,
again suggesting that the eﬀect of perceived
beneﬁts on the decision to take medication is
largely because of their eﬀect on taking anti-
depression medication. With respect to surgery,
as for medications, the importance of perceived
beneﬁts is signiﬁcant in predicting action, but
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the importance of perceived costs, while nega-
tive, is not; for these decisions, none of the
interactions is signiﬁcant. For screening, it is the
importance of perceived costs, that is signiﬁcant
and negative, whereas the importance of per-
ceived beneﬁts, while positive, is not.
The second alternative model considered the
possibility that it was not speciﬁc perceived
beneﬁts and costs, but the importance attached
to one particular reason – following the HCPs
advice – that determined whether the respondent
took action or not. We construe the HCPs
advice as a heuristic for the net beneﬁt (or cost)
associated with a particular medical decision.
Patients who considered this highly important
would tend to act if the HCP recommended
action and would not act if the HCP recom-
mended against it. For purposes of this analysis,
we treated the HCP variable as binary, coded 1
if respondents rated the importance of following
the HCPs advice as ten and 0 if they gave it any
Table 3 Logit coefﬁcients and standard errors from logistic
regression model predicting (a) medication initiation (b)
surgery, and (c) cancer screening from difference between
average importance ratings of beneﬁts and costs (mean_diff)
Coefﬁcient
Standard
error
(a)
Intercept )0.542 0.44
Modules
Cholesterol 0.829** 0.255
High blood pressure 0.864** 0.293
Depression – –
Mean_diff 0.158** 0.057
Cholesterol · mean_diff )0.142* 0.062
High_BP · mean_diff )0.163* 0.065
Gender (1 = female) )0.033 0.165
Age )0.0083 0.0059
Race
White – –
Black 0.715** 0.265
Other 0.077 0.292
Hispanic origin (1 = yes) 0.043 0.352
Education
HS or less – –
Some college )0.543** 0.187
College graduate )0.437* 0.174
Number of observations 1942
Number of respondents 1575
(b)
Intercept )2.102* 0.974
Modules
Surgery for lower-back pain )0.953* 0.456
Cataract surgery 0.582 0.425
Knee ⁄ hip replacement – –
Mean_Diff 0.167* 0.081
Backpain · mean_diff 0.246 0.13
Cataract · mean_diff )0.023 0.103
Gender (1 = female) )0.018 0.294
Age 0.030* 0.013
Race
White – –
Black )0.332 0.434
Other )2.024* 0.925
Hispanic origin (1 = yes) 1.834* 0.831
Education
HS or less – –
Some college 0.644 0.383
College graduate )1.138** 0.349
Number of observations 448
Number of respondents 425
Table 3 Continued
Coefﬁcient
Standard
error
(c)
Intercept )0.695 0.621
Modules
Colon cancer screening )0.009 0.38
Breast cancer screening 0.79 0.431
Prostate cancer screening – –
Mean_Diff 0.233** 0.076
Colon · mean_diff )0.16 0.086
Breast · mean_diff 0.035 0.097
Gender (1 = female) )0.385 0.225
Age 0.032** 0.008
Race
White – –
Black 0.207 0.264
Other 0.478 0.341
Hispanic origin (1 = yes) )0.14 0.389
Education
HS or less – –
Some college )0.066 0.223
College graduate )0.188 0.192
Number of observations 2081
Number of respondents 1758
*P < 0.05, **P < 0.01.
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other rating.2 The eﬀect of the HCP variable is
signiﬁcant and positive for all three types of
decisions (data not shown); none of the inter-
actions between following the HCPs advice and
speciﬁc medical conditions is signiﬁcant.
Which of these three alternative models
explains the greatest amount of variance in
the dependent variable, the decision to take
action with respect to a particular medical con-
dition? Nagelkerkes (22) max-rescaled R2 esti-
mates,3 which can be interpreted as roughly
comparable to a measure of the variance
explained by the model, are shown in Table 4 for
each of the three models and each of the three
types of decisions.
As can be seen in Table 4, the three models
lead to very similar conclusions. (Note that
comparisons can legitimately be made only
across models on the same population. Because
of diﬀerences in the individuals involved, one
cannot compare the amount of variance
explained for surgery, for example, with either of
the other two types of decisions.) Perceived
beneﬁts and costs, whether modelled as the dif-
ference between the importance of beneﬁts and
costs, or as two separate predictors, or as the
heuristic of following ones HCPs advice,
account for roughly similar amounts of variance
in each type of decision.
Hypothesis 2 states that the greater the dif-
ference between the importance attached to
beneﬁts and costs, the greater the conﬁdence in
the decision will be – that is, the more certain
respondents will be that the decision they made
was the correct one. This relationship is
hypothesized because a greater diﬀerence in the
importance of beneﬁts and costs implies less
conﬂict with respect to taking action.
Conﬁdence in ones decision to take action or
not was assessed by means of the following
question, which was asked prior to the question
about how important various reasons were in
thinking about the decision:
On a scale from zero to 10, where 0 means not
at all conﬁdent and 10 means extremely conﬁ-
dent, how conﬁdent are you that the decision (to
take medication, undergo screening, have sur-
gery) was the right one?
We tested this hypothesis separately for each
type of decision by means of linear regression,
controlling for gender, age, education, race,
Hispanic origin, and whether the respondent
took action or not, as well as the interaction
between taking action and the diﬀerence
between the importance attached to perceived
beneﬁts and costs.
Table 4 Estimates of variance explained (Nagelkerkes R2) by models using three different cost-benefit measures plus demo-
graphic controls for three types of medical decisions*
Estimates of variance explained (Nagelkerkes R2)
Importance measure Started medication Had surgery Had screening
Mean difference between beneﬁts and costs 0.07 0.40 0.13
Mean pros and mean cons 0.11 0.50 0.15
Importance of following health-care providers advice 0.12 0.41 0.11
*Each of the nine models includes the importance measure, the decision modules (e.g. colon cancer, breast cancer for screening), interactions
between the importance measure and the decision modules, and demographic characteristics (gender, age, race, Hispanic origin and education).
2By far the largest fraction of respondents selected 10
(extremely important) as the importance rating for the HCPs
advice: For initiating medication – cholesterol-lowering,
51%; blood pressure, 60%; anti-depressants, 45%; for sur-
gery – knee ⁄ hip, 62%; cataract, 68%; lower-back pain, 52%;
for cancer screening – colon, 46%; breast, 60%; prostate,
47%.
3No single index equivalent to R2 in ordinary least squares
(OLS) regression exists for logistic regression but several
pseudo R2 indices have been developed. However, Hosmer
and Lemeshow (23) note that the pseudo R2 indices tend to
be smaller than R2 values for equivalent OLS analyses and
caution against misperceptions of these lower values as
indicating poor models. The Cox and Snell (24) pseudo R2
measure yields a coeﬃcient similar in size to Hosmer and
Lemeshows pseudo R2. However, this index is diﬃcult to
interpret as its maximum value is <1 and depends on the
proportion of cases versus controls in the sample. To
facilitate interpretation, the Nagelkerke index transforms the
Cox and Snell index to a 0–1 scale.
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The diﬀerence between the importance of
perceived beneﬁts and costs is signiﬁcantly
related to conﬁdence with respect to all three
types of medical decisions (medication: regres-
sion coeﬃcient = 0.1765, SE = 0.0238, P <
0.001; surgery: regression coeﬃcient = 0.0871,
SE = 0.0386, P < 0.05; screening: regression
coeﬃcient = 0.1170, SE = 0.0277, P < 0.001).
And except for starting medication, those who
decided to take action are signiﬁcantly more
conﬁdent that they made the right decision than
those who decided not to act (medication:
regression coeﬃcient = 0.0658, SE = 0.1130,
P < 0.56; surgery: regression coeﬃcient =
0.8604, SE = 0.2135, P < 0.001; and screening:
regression coeﬃcient = 2.8229, SE = 0.2938,
P < 0.001).
Discussion and conclusions
Many factors may aﬀect patients medical deci-
sions. These diﬀer from one decision type to
another, and even across speciﬁc decisions
within a particular type. However, the results of
aggregating individual factors into those that
may be regarded as beneﬁts and those that may
be regarded as costs suggest that certain general
principles underlie the decisions. The impor-
tance attributed to perceived beneﬁts and costs is
signiﬁcantly related, in the expected direction, to
a wide variety of medical decisions, and it is also
signiﬁcantly related to the conﬁdence patients
have in those decisions.
Because the measures of importance were
ascertained after the decisions themselves, we
cannot assert that the perceived beneﬁts and
costs caused these decisions. But there is a con-
sistent and statistically signiﬁcant relationship
between action and the importance of perceived
costs and beneﬁts, whether these are modelled as
individual predictors or combined into a single
measure or whether following the doctors
advice is used as a heuristic for a decisions net
beneﬁt or cost. In general, the importance rat-
ings of reasons that can be viewed as beneﬁts are
signiﬁcantly associated with a tendency to act;
the importance ratings of reasons that can be
viewed as costs are signiﬁcantly associated with
a tendency not to act, although the strength of
those relationships varies from one type of
decision to another.
The fact that patients appear to weigh beneﬁts
and costs in making medical decisions does not
mean that they are well informed, in the sense of
knowing which beneﬁts and costs are considered
most important by medical experts or having
accurate information about treatment options
and their consequences (25). Two other articles
based on this study provide evidence for this.
Fagerlin et al. (18) document the fact that the
patients in this sample were by and large not
knowledgeable about important facts related to
the decision they had made, and Sepucha et al.
(26) show that whether or not patients regard
themselves as well informed bears little rela-
tionship to their actual knowledge scores.
Our conclusion about the role of beneﬁts and
costs in medical decision making might be
challenged on the grounds that people attempt
to justify their decisions after the fact or to
reduce what Festinger (27) referred to as cog-
nitive dissonance. However, if attempts to
reduce cognitive dissonance were the only
explanation involved, we would expect the
relationship between the ratings of beneﬁts and
costs and the decision to be stronger than it
actually is.
The ﬁndings and conclusions above are lim-
ited by the retrospective design of the study.
Sample members were asked whether, in the past
2 years, they had ever made a particular medical
decision or talked to a HCP about such a deci-
sion. Although the 2-year time frame was chosen
to maximize sample size and minimize forget-
ting, some forgetting inevitably occurs, and only
those who could recall an action or discussion
were included in the sample. Thus, people whose
responses made them eligible for inclusion are
biased towards those who, for whatever reason,
were more likely to recall a decision or a dis-
cussion with their medical provider. Exclusion of
those for whom the decision had little salience
may therefore overestimate the rationality of the
general population. At the same time, because of
the 2-year recall period, sample members may
have forgotten some details of the decision,
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which may also lead to less accurate estimates of
the decisions rationality.
A second limitation of the ﬁndings arises from
the studys eligibility rules. Those who consid-
ered one of the decisions but never spoke to a
HCP about it have no chance of inclusion in the
sample. For example, those for whom cost is an
important deterrent may not have a regular
HCP; and those who are terriﬁed by the possible
complications of elective surgery may never raise
the issue with their doctor. As a result, both
groups would have been excluded from the
sample, and measures of the importance of
various reasons may be biased by their exclu-
sion.
The variance explained in decisions about
medication and screening is relatively small,
suggesting either that not all factors important
to patients were included in the survey, or that
these actions are not presented to patients as
requiring a decision. Future work in this area
should try to uncover the reasons for the lack of
explanatory power to improve the decisions
patients make and how satisﬁed they are with
those decisions.
Despite these limitations, the study provides
important evidence, consistent with other
research, that beneﬁt-cost calculations inform
patients medical decision making. What is
equally important, however, is that the impor-
tance attached to speciﬁc costs and beneﬁts
varies from one individual to another. This
article has dealt with the implications of bene-
ﬁt-cost calculations for medical decision mak-
ing in general. But to be useful to individual
patients, HCPs must take time to discover how
a particular patient facing a particular decision
evaluates its speciﬁc beneﬁts and costs for him-
or herself. In discussing a decision about sur-
gery, for example, one patient may give high
importance to being able to function better, but
may attach even greater importance to the
possibility of serious side eﬀects. For another
patient, this calculus may be reversed. Only if
HCPs are alert to such individual preferences
can truly informed shared decision making
come about.
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